## 1. Purpose

To establish and describe the Office of Sponsor and Regulatory Oversight's (OSRO) Temperature Excursions of Investigational Product During Storage and Shipping policy.

## 2. Scope

2.1. OSRO in the Center for Cancer Research (CCR), National Cancer Institute (NCI) shall establish and control the policy.

2.2. Investigators, research team members, other departmental personnel, and external NIH collaborators and contractors when they are working on studies conducted under a CCR-held Investigational New Drug (IND) application or Investigational Device Exemption (IDE), participating in a CCR-supported Non-Significant Risk Device Study (NSR) or supported by a CCR-held Master File under OSRO oversight shall comply with the policy.

2.3. Limitations

2.3.1. This policy does not apply to personnel working on studies that are not under a CCR-held IND, IDE, or is an NSR device study and/or when no OSRO oversight or interdepartmental collaboration is required.

2.3.2. Nothing in this policy will supersede NCI, National Institutes of Health (NIH) or Health and Human Services (HHS) requirements.

## 3. Responsibilities

3.1. The Center for Cancer Research Management is committed to providing resources to meet the requirements for implementing a Temperature Excursions of Investigational Product During Storage and Shipping policy within OSRO and supporting its continual improvement.

3.2. OSRO personnel are responsible for understanding and using the Temperature Excursions of Investigational Product During Storage and Shipping policy.

3.3. The OSRO Director is responsible for establishing and maintaining the Temperature Excursions of Investigational Product During Storage and Shipping policy.

3.4. OSRO Sponsor and Regulatory Oversight Support (SROS) Contractor staff assisting OSRO Functional Groups are responsible for understanding the Temperature Excursions of Investigational Product During Storage and Shipping policy.

## 4. References

4.1. ICH E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) Guidance for Industry (FDA), March 2018

4.2. ICH E6(R3) Good Clinical Practice (GCP) draft Guidance for Industry (FDA), May 2023

4.3. 21 CFR Part 312 – Investigational New Drug Application

4.4. 21 CFR Part 812 – Investigational Device Exemptions

4.5. United States Pharmacopeia/National Formulary (USP/NF) General Chapter <659> Packaging and Storage Requirements

4.6. 101-S01 Good Documentation Practices

## 5. Definitions

Refer to the OSRO Lexicon.

## 6. Policy

6.1. Investigational products (IPs) must be transported, handled, and stored in a manner that ensures that the temperature requirements defined in the study protocol can be maintained. Excursions from the pre-defined temperature range may affect study product performance and stability, as well as impact trial participants' safety.

6.2. OSRO Pharmaceutical Management defines a temperature excursion as a temperature deviation that meets *all* the following criteria:

6.2.1. Outside of the standard temperature range, *and*

6.2.2. Outside of any acceptable storage/shipping temperature as defined in the individual protocol, Investigator's Brochure, commercial package insert, product labeling, Pharmacy Manual, or in documented communication from the manufacturer or sponsor (i.e., OSRO), *and*

6.2.3. Outside the acceptable time out of range as defined in the individual protocol, Investigator's Brochure, commercial package insert, Pharmacy Manual, or in documented communication from the manufacturer or sponsor (i.e., OSRO), *and*

6.2.4. After the numerical rounding conventions listed in OSRO SOP 101-S01 (Reference 4.6) are applied.

6.3. OSRO Pharmaceutical Management assesses the potential impact on the quality, strength, purity and/or identity of an IP that has experienced a temperature excursion.

6.3.1. Analytical data, empirical data, opinions from the manufacturer and other subject matter experts, historical data and pharmaceutical guidance (e.g., USP, FDA) may be used in the assessment.

6.4. OSRO Pharmaceutical Management must be notified of any temperature excursion experienced by an IP during storage or shipping as soon as possible.

6.5. In the event of a temperature excursion, the IP in question must be quarantined in the appropriate storage conditions until the IP is deemed acceptable for use by OSRO.

6.5.1. Quarantined inventory should be separated from other IPs and clearly marked as not for clinical use.

6.6. The owner of the equipment which experienced the temperature excursion investigates the root cause of the temperature excursion per their procedure. The root cause investigation and corrective and preventative actions should be provided to OSRO Pharmaceutical Management.

6.7. The affected IP cannot be dispensed to a study participant until OSRO Pharmaceutical Management notifies the clinical site and/or storage site that the IP may be released from quarantine and returned to clinical supply.

## 7. Change Summary

| Revision Number | Effective Date | Description of Change |
|---|---|---|
| 1 | 15JUL2024 | New Document |